Grant Hawthorne
Directeur des opérations chez NRG Therapeutics Ltd.
Profil
Grant Hawthorne is currently the Chief Operating Officer at NRG Therapeutics Ltd.
He previously worked as the Chief Operating Officer at Auspherix Ltd.
from 2015 to 2019.
Prior to that, he was a Partner at Boundary Capital Partners LLP.
Postes actifs de Grant Hawthorne
| Sociétés | Poste | Début |
|---|---|---|
NRG Therapeutics Ltd.
 NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Directeur des opérations | - |
Anciens postes connus de Grant Hawthorne
| Sociétés | Poste | Fin |
|---|---|---|
Auspherix Ltd.
 Auspherix Ltd. BiotechnologyHealth Technology Auspherix Ltd. operates as an early stage anti-infectives company which develops novel antibiotics to treat resistant bacterial diseases. The firm uses a library screening approach to identify drugs with novel mechanisms of action as antibiotics. The company was founded by Ian Charles and Dagmar Alber in 2013 and is headquartered in Stevenage, the United Kingdom. | Directeur des opérations | 30/04/2019 |
Boundary Capital Partners LLP
 Boundary Capital Partners LLP Investment ManagersFinance Boundary Capital Partners LLP (Boundary Capital) is a venture capital firm founded in 2009. The firm is headquartered in London. | Private Equity Investor | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
NRG Therapeutics Ltd.
NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Commercial Services |
Auspherix Ltd.
Auspherix Ltd. BiotechnologyHealth Technology Auspherix Ltd. operates as an early stage anti-infectives company which develops novel antibiotics to treat resistant bacterial diseases. The firm uses a library screening approach to identify drugs with novel mechanisms of action as antibiotics. The company was founded by Ian Charles and Dagmar Alber in 2013 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Boundary Capital Partners LLP
Boundary Capital Partners LLP Investment ManagersFinance Boundary Capital Partners LLP (Boundary Capital) is a venture capital firm founded in 2009. The firm is headquartered in London. | Finance |